Atzumi, a dihydroergotamine (DHE) nasal powder, was approved by the Food and Drug Administration (FDA) for the acute ...

The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals' self-administered migraine drug, giving way to a ...

St. Renatus LLC, a Fort Collins-based biopharmaceutical company that won Food and Drug Administration approval nine years ago ...

MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company ...

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The FDA ap­proved a new nasal spray for mi­graines that was de­vel­oped by Sat­suma Phar­ma­ceu­ti­cals.

The FDA approval for Atzumi is based on two clinical ... However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and ...

The FDA has approved Satsuma’s STS101 dihydroergotamine (DHE ... but the currently-available injectable and liquid nasal spray dosage forms have significant drawbacks that result in limited ...